ArticleJournal of investigative medicine : the official publication of the American Federation for Clinical Research2021

Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2.

Joseph I Clark et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.